Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C102H193N2O21P |
| Molecular Weight | 1814.5984 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 13 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)N[C@H]1[C@H](OC[C@H]2OC(O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H]2O)O[C@H](CO)[C@@H](OP(O)(O)=O)[C@@H]1OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC
InChI
InChIKey=JWBXGVSYUHYUJY-MOYMLGNLSA-N
InChI=1S/C102H193N2O21P/c1-7-13-19-25-31-37-40-42-43-45-48-54-60-65-71-77-92(109)120-85(74-68-62-56-50-35-29-23-17-11-5)80-90(107)104-96-100(124-94(111)81-86(75-69-63-57-51-36-30-24-18-12-6)121-93(110)78-72-66-58-52-46-39-33-27-21-15-9-3)99(125-126(115,116)117)87(82-105)123-102(96)118-83-88-97(112)98(113)95(101(114)122-88)103-89(106)79-84(73-67-61-55-49-34-28-22-16-10-4)119-91(108)76-70-64-59-53-47-44-41-38-32-26-20-14-8-2/h84-88,95-102,105,112-114H,7-83H2,1-6H3,(H,103,106)(H,104,107)(H2,115,116,117)/t84-,85-,86-,87-,88-,95-,96-,97-,98-,99-,100-,101?,102-/m1/s1
| Molecular Formula | C102H193N2O21P |
| Molecular Weight | 1814.5984 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 12 / 13 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:08:57 GMT 2025
by
admin
on
Mon Mar 31 23:08:57 GMT 2025
|
| Record UNII |
C51W8V7996
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
253119-91-4
Created by
admin on Mon Mar 31 23:08:57 GMT 2025 , Edited by admin on Mon Mar 31 23:08:57 GMT 2025
|
PRIMARY | |||
|
9833899
Created by
admin on Mon Mar 31 23:08:57 GMT 2025 , Edited by admin on Mon Mar 31 23:08:57 GMT 2025
|
PRIMARY | |||
|
C51W8V7996
Created by
admin on Mon Mar 31 23:08:57 GMT 2025 , Edited by admin on Mon Mar 31 23:08:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Mechanism of Action: Nitric oxide synthase stimulants, Highest Development Phase: Discontinued for Ischaemic heart disorders and Reperfusion injury
|
||
|
ACTIVE MOIETY |
In contrast with monophosphoryl lipid A (MLA), which has also been reported to be cardioprotective at similar doses in dogs, RC-552 was approximately 100 times less prone to cause fever in the USP rabbit pyrogen test. Likewise, RC-552 did not induce secretion of the proinflammatory cytokines TNF, IL-6 or IL-8 from THP-1 cells or alter the expression of adhesion molecules on human neutrophils at concentrations up to 10 microg/ml.
|